AMENDMENT NO. 1 AGREEMENT to the Amended and Restated License Agreement dated 26 September 2003 between Elan Corporation, plc and Acorda Therapeutics, Inc. and to the Supply Agreement dated 26 September 2003 between Elan Corporation, plc and Acorda...Amendment No. 1 Agreement • August 10th, 2009 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This AMENDMENT NO. 1 AGREEMENT and CONSENT TO SUBLICENSE (the “Amendment and Consent Agreement”) dated as of the 30th day of June, 2009 (the “Effective Date”) is by and among Elan Pharma International Limited, a company incorporated under the laws of Ireland and having its registered office at Monksland, Athlone, County Westmeath, Ireland (“Elan”), Acorda Therapeutics, Inc., a Delaware corporation with an office at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”), and Biogen Idec International GmbH , a Swiss company with an office at Landis & Gyr Strasse 3, CH-6300 Zug, Switzerland (“Biogen”). Elan, Acorda and Biogen are each a “Party” and collectively, the “Parties”.
SUPPLY AGREEMENT BETWEENSupply Agreement • August 10th, 2009 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This Supply Agreement (the “Agreement”) is entered into as of the 30th day of June 2009 (the “Effective Date”) by and between Acorda Therapeutics, Inc., a company organized under the laws of the State of Delaware with its principal place of business at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”), and Biogen Idec International GmbH, a company organized under the laws of Switzerland, with its principal place of business at Landis & Gyr Strasse 3, CH-6300 Zug, Switzerland (“Licensee”) (hereinafter, each of Licensee and Acorda, a “Party” and, collectively, the “Parties”).
